Mounjaro is a “GIP/GLP-1 receptor agonist” that acts not only on GLP-1 receptors but also on GIP receptors. Its mechanism of action differs from drugs such as Ozempic, Rybelsus and Wegovy, which act only on GLP-1 receptors.
In this article, we compare Mounjaro (generic name: tirzepatide) and GLP-1 receptor agonists in terms of mechanism of action, weight-loss effect, side effects, administration, and the indications approved in Japan. Because even the same ingredient can have different target patients and insurance conditions depending on the brand name, we organize the information based on the situation in Japan as of September 2026.
The short answerIf you’re busy, just read this
- Mounjaro does not act on GLP-1 alone; it acts on two receptors, GIP and GLP-1.
- Even though both contain tirzepatide, in Japan Mounjaro is mainly approved for type 2 diabetes, while Zepbound is mainly approved for conditions such as obesity disease that meets certain criteria.
- It is important to choose with your doctor, considering not only effectiveness but also the approved uses, side effects, administration, cost and ongoing consultations.
What are GLP-1 drugs? How they basically work
GLP-1 receptor agonists are drugs used in both obesity treatment and diabetes treatment through two actions: blood sugar control and appetite suppression. GLP-1 (glucagon-like peptide-1) is a hormone secreted from the small intestine when you eat, and it is one of a group of hormones called “incretins.” Incretins play an important role in promoting the secretion of insulin, which lowers blood sugar. GLP-1 is naturally present in the body, but because it has a short half-life and is broken down quickly, its application to obesity and diabetes treatment was limited.
That is why “GLP-1 receptor agonists” were developed. They are artificially made drugs designed to keep the action of GLP-1 stable and long-lasting.
The main mechanisms of action of GLP-1 drugs
GLP-1 receptor agonists work on weight loss and blood sugar improvement mainly through three pathways.
- Blood sugar control
When blood sugar rises after a meal, it acts on the beta cells of the pancreas to promote insulin secretion. At the same time, it acts on the alpha cells of the pancreas to suppress the secretion of glucagon, which raises blood sugar. This dual action helps prevent sharp rises in blood sugar. - Appetite suppression
It acts directly on the appetite center in the hypothalamus of the brain, enhancing the feeling of fullness. It also slows gastric emptying so that food stays in the stomach longer, and this lasting “full” feeling also helps suppress appetite. - Weight-loss effect
As calorie intake naturally decreases, a reduction in fat mass can be expected over the long term. Together with improved glucose metabolism, it is helpful not only for obesity disease but also for preventing lifestyle-related diseases.
Main GLP-1-related drugs used in Japan
Even with the same active ingredient, the uses approved in Japan differ by brand name. Their main positioning as of September 2026 is as follows.
- Ozempic (semaglutide)A GLP-1 receptor agonist injected once weekly. Its approved indication is type 2 diabetes.
- Rybelsus (semaglutide)An oral GLP-1 receptor agonist taken once daily. Its approved indication is type 2 diabetes.
- Wegovy (semaglutide)A drug for obesity disease injected once weekly. It is used when certain requirements are met, such as BMI, health problems, treatment history and facility requirements.
- Mounjaro (tirzepatide)A GIP/GLP-1 receptor agonist injected once weekly. Its approved indication is type 2 diabetes.
- Zepbound (tirzepatide)A drug for obesity disease containing the same active ingredient as Mounjaro. Its approved uses and conditions of use differ from Mounjaro’s.
Saxenda (liraglutide), which is used for obesity treatment overseas, is not approved as a drug for obesity disease in Japan. It is important to check not just the drug name but also the indications approved in Japan.
Features and mechanism of action of Mounjaro (tirzepatide)
Mounjaro is the world’s first “dual agonist” that acts on two hormones, GLP-1 and GIP, at the same time, and stronger blood sugar improvement and weight-loss effects than conventional GLP-1 drugs have been reported.
2-1. What is tirzepatide?
Mounjaro is the product name, and the active ingredient (generic name) is tirzepatide. In Japan, Mounjaro is approved as a treatment for type 2 diabetes, and Zepbound, which contains the same active ingredient, is approved as a treatment for conditions such as obesity disease that meets certain criteria. Different brand names mean different approved uses and conditions of use.
2-2. GLP-1 and GIP: the roles of two incretins
The reason tirzepatide differs from conventional GLP-1 receptor agonists is that it acts on two types of receptors.
Action on GLP-1 receptors
It promotes insulin secretion according to blood sugar levels and suppresses glucagon secretion and gastric emptying, which is involved in blood sugar management and regulating appetite.
Action on GIP receptors
It promotes insulin secretion according to blood sugar levels. Combined with the action on GLP-1 receptors, it is thought to contribute to improved blood sugar and weight management.
A drug should not be chosen on its mechanism of action alone; the doctor decides taking into account the diagnosis, medical history, concomitant medications, side effects and treatment goals.
2-3. Effects seen in clinical trial data
The effects of drugs cannot simply be compared across trials that differ in participants, doses, treatment duration, lifestyle interventions and so on. It is important to focus on the results of head-to-head trials.
SURPASS-2 trial in patients with type 2 diabetes
Over 40 weeks, the mean weight changes in the tirzepatide 5 mg, 10 mg and 15 mg groups were −7.6 kg, −9.3 kg and −11.2 kg respectively, and −5.7 kg in the semaglutide 1 mg group.
SURMOUNT-5 trial in adults with obesity without type 2 diabetes
The mean percentage weight change over 72 weeks, comparing the maximum tolerated doses, was −20.2% in the tirzepatide group and −13.7% in the semaglutide group.
Both are averages for groups and do not mean that you will get the same results or that tirzepatide is suitable for everyone. Which drug can be used for treatment in Japan is decided by a doctor based on the approved indications and the patient’s condition.
2-4. Administration and convenience
- Administration: subcutaneous injection once weekly (using an injection pen)
- Dose: starts at 2.5 mg and can be increased step by step to 5 mg, 10 mg and 15 mg
- Can be self-injected, making it easy to fit into your lifestyle
Compared with Saxenda, which requires daily injections, the convenience of only once weekly is a major advantage. Some people also ask about changing the dose on their own, such as “wouldn’t injecting two 2.5 mg pens have the same effect as 5 mg?”, but the safety and effectiveness of use outside the approved dosage and administration have not been confirmed. Always consult your doctor about decisions on dose increases or combinations.
2-5. Side effects and precautions
While Mounjaro has strong effects, the following side effects have also been reported.
- Nausea, diarrhea, constipation, loss of appetite (common early in treatment)
- Temporary fatigue
- Rarely, a risk of pancreatitis or gallstones
In particular, because weight loss may progress rapidly, attention needs to be paid to nutritional balance and maintaining muscle mass. Use during pregnancy or breastfeeding is not recommended.
Comparing Mounjaro and the main GLP-1-related drugs
The biggest difference is that Mounjaro acts on two receptors, GIP and GLP-1, whereas Ozempic, Rybelsus and Wegovy act on GLP-1 receptors.
| Brand name | Active ingredient | Action | Administration | Main uses approved in Japan |
|---|---|---|---|---|
| Mounjaro | Tirzepatide | GIP+GLP-1 | Once-weekly injection | Type 2 diabetes |
| Zepbound | Tirzepatide | GIP+GLP-1 | Once-weekly injection | Obesity disease meeting certain criteria, etc. |
| Ozempic | Semaglutide | GLP-1 | Once-weekly injection | Type 2 diabetes |
| Rybelsus | Semaglutide | GLP-1 | Once-daily oral | Type 2 diabetes |
| Wegovy | Semaglutide | GLP-1 | Once-weekly injection | Obesity disease meeting certain criteria |
Key point
Mounjaro is often broadly described as “a GLP-1 drug,” but strictly speaking it is a GIP/GLP-1 receptor agonist. Also, even though they contain the same ingredient, Mounjaro and Zepbound differ in their approved uses and conditions of use.

Side effects and safety
The most common side effects of GLP-1 receptor agonists, including Mounjaro, are digestive symptoms such as nausea and diarrhea; most occur early in treatment and tend to ease over time. GLP-1 receptor agonists and Mounjaro (tirzepatide) have shown effectiveness in many clinical trials, but side effects are not zero. When using them for medical weight loss, it is important to understand the risks as well as the effects. Here we explain the typical side effects and key safety points.
4-1. Digestive symptoms (the most common side effects)
These side effects are common to GLP-1 drugs and are also seen frequently with Mounjaro.
Nausea / vomiting
Especially common after the first dose and early after a dose increase.
Diarrhea
Caused by increased intestinal movement.
Constipation
Conversely, it may also occur because gastrointestinal movement is suppressed.
Loss of appetite / stomach heaviness
Occurs when the appetite-suppressing effect is too strong.
In most cases the body adjusts as treatment continues, and symptoms ease within a few weeks to a few months. To keep side effects down, Mounjaro is basically started at a low dose and increased step by step.
4-2. Risk of hypoglycemia
When GLP-1 drugs are used alone, hypoglycemia is relatively rare. This is because the actions of GLP-1 and GIP are based on a mechanism that “promotes insulin only when blood sugar is high.” However, caution is needed when they are combined with other blood sugar-lowering drugs such as insulin or sulfonylureas, as the risk of hypoglycemia increases.
4-3. Precautions related to weight loss
Because Mounjaro has a strong weight-loss effect, weight may drop considerably in a short period. The following risks have been pointed out in connection with this.
Loss of muscle mass
Muscle may be lost along with fat.
Risk of gallstones
Rapid weight loss can promote gallstone formation.
Nutritional deficiency
Appetite may drop so much that you cannot get the nutrients you need.
For this reason, doctors combine nutritional guidance and exercise therapy to support weight loss without strain.
4-4. Serious side effects reported in rare cases
Pancreatitis
If you have severe abdominal pain or back pain, see a doctor right away.
Gallbladder disease
The risk of developing gallstones or cholecystitis is said to increase slightly.
Possible thyroid C-cell tumors (animal studies)
The relevance in humans has not been established, but caution is needed for people with a history of thyroid tumors.
Although these are rare, they are checked through the pre-treatment interview and regular consultations.
4-5. Safety evidence
In the SURPASS and SURMOUNT trials, the adverse events commonly seen with tirzepatide were digestive symptoms such as nausea, diarrhea and constipation, and most of these were mild to moderate. Because the frequencies differ depending on the trial participants, doses and duration, the percentages from different trials cannot be combined into a single number.
4-6. What to tell your doctor before use
If you are pregnant or breastfeeding, have a history of pancreatitis or gallbladder disease, have a severe gastrointestinal disorder, or are using diabetes medications, be sure to tell your doctor before it is prescribed. Whether you can use it is decided individually based on the latest electronic package insert and your condition.
Do not combine drugs or change the dose on your own.
If you are wondering whether Mounjaro suits your constitution, why not start by talking with a doctor in a counseling session?
Cost and insurance coverage depend on the purpose of treatment
Not all GLP-1 receptor agonists and GIP/GLP-1 receptor agonists are self-pay treatment. When they are used to treat an approved disease and meet the requirements for insurance-covered care, they may be covered by public health insurance. On the other hand, use for cosmetic, slimming or weight-loss purposes is self-pay treatment.
- Mounjaro, Ozempic, RybelsusMay be covered by health insurance when used to treat type 2 diabetes and the requirements are met.
- Zepbound, WegovyMay be covered by health insurance when used to treat obesity disease meeting certain criteria and the requirements for patients, medical institutions, etc. are met.
- For cosmetic or slimming purposesThis is self-pay treatment and you pay the full cost yourself.
For the cost of self-pay treatment at Hiro Clinic, please see our price page. Detailed conditions for insurance coverage are also explained in our article on insurance coverage for Mounjaro.
Not sure if it suits you? Start with a consultation.
A doctor decides whether you can use it and which dose is appropriate, based on your consultation and questionnaire.
No consultation fee (first & follow-up visits)Online consultation available
How to choose between Mounjaro and GLP-1 drugs
Don’t decide based only on “the drug that makes you lose the most weight”; compare treatment goals and the conditions under which you can continue safely.
- Treatment goalTreating type 2 diabetes, or treating medically diagnosed obesity disease
- Mechanism of actionGLP-1 alone, or dual GIP/GLP-1 action
- AdministrationOnce-weekly injection, or daily oral medication
- SafetyWhether gastrointestinal symptoms, hypoglycemia risk, medical history and concomitant medications can be taken into account
- SustainabilityWhether you can continue comfortably, including cost, consultations, tests and nutritional management
Key point
Don’t switch or combine drugs on your own; choose after consulting your doctor.
About self-pay treatment and off-label use
Frequently asked questions about Mounjaro (tirzepatide)
QIs Mounjaro a GLP-1 drug?
Because it acts not only on GLP-1 receptors but also on GIP receptors, strictly speaking it is a GIP/GLP-1 receptor agonist.
QWhich is better, Rybelsus or Mounjaro?
Rybelsus is taken orally once daily, and Mounjaro is injected once weekly. You choose with your doctor, considering your treatment goals, chronic conditions, concomitant medications, side effects and how easy it is to continue.
QWhat are the drawbacks of Mounjaro?
Digestive symptoms may occur, and it requires once-weekly self-injection and regular consultations. For weight-loss purposes it is self-pay treatment, with ongoing costs.
QIs there a drug that leads to more weight loss than Mounjaro?
There is no drug that can be said to cause “the most weight loss” for everyone. In the SURMOUNT-5 trial, the mean percentage weight change was −20.2% in the tirzepatide group and −13.7% in the semaglutide group, but these are group averages under specific conditions.
QCan Mounjaro be combined with GLP-1 drugs?
Please avoid combining them on your own. Switching or combining drugs is decided by a doctor who has checked your current prescriptions.
QCan Mounjaro be used for obesity treatment in Japan?
In Japan, Mounjaro is approved for type 2 diabetes. Use for weight loss is off-label use under self-pay treatment. Zepbound, which contains the same ingredient, is approved for conditions such as obesity disease that meets certain criteria.
Not sure? Talk to us
No consultation fee (first & follow-up visits)Online consultation available
Toll-free 0120-241-929 (toll-free in Japan, 9:00–18:00 JST, Japanese only)
Summary: Mounjaro and GLP-1 drugs differ in action, approved uses and administration
Mounjaro is a GIP/GLP-1 receptor agonist that acts on two receptors, GIP and GLP-1. Its mechanism of action differs from drugs that act only on GLP-1 receptors, and it also differs from Zepbound, which contains the same ingredient, in the uses and conditions of use approved in Japan.
When choosing a drug, consult your doctor about not only the figures for weight-loss effect but also your treatment goals, medical history, concomitant medications, side effects, administration, cost and ongoing consultations.
Who to contact if side effects occur | When to see a doctor
If any of the following symptoms occur, please contact us rather than waiting to see on your own judgment. GIP/GLP-1 receptor agonists, including Mounjaro, are known to cause side effects, mainly digestive symptoms. Most are mild, but in rare cases they can be serious.
| Symptom | Possible cause | What to do |
|---|---|---|
| Nausea or vomiting that continues | Digestive symptoms; the most common side effect | Please contact us if you continue to be unable to keep fluids down |
| Severe abdominal pain (pain that goes through to the back) | Possible acute pancreatitis | Stop the injections immediately and see a doctor |
| Cold sweats, palpitations, strong hunger, feeling dazed or confused | Hypoglycemia | Take some sugar right away and contact us |
| Skin rash, difficulty breathing, swelling of the face or throat | Allergic reaction | See a doctor immediately |
If symptoms are severe outside these hours, go to your nearest emergency medical facility.
Direct phone numbers for each clinic are listed on the clinic information page.
References
The information on medications in this article is based on the following official sources. For details on dosage, administration and side effects, always check the latest electronic package insert.
- Pharmaceuticals and Medical Devices Agency (PMDA): Mounjaro subcutaneous injection Ateos, electronic package insert
- PMDA: Drug Guide for Patients, Mounjaro subcutaneous injection Ateos (PDF)
- Ministry of Health, Labour and Welfare: Prevention of lifestyle-related diseases
Cited literature
- Frías, Juan P., et al. ‘Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes’. New England Journal of Medicine, vol. 385, no. 6, Aug. 2021. DOI.org (Crossref), https://doi.org/10.1056/NEJMoa2107519.
- Jastreboff, Ania M., et al. ‘Tirzepatide Once Weekly for the Treatment of Obesity’. New England Journal of Medicine, vol. 387, no. 3, July 2022, pp. 205–16. DOI.org (Crossref), https://doi.org/10.1056/NEJMoa2206038.
- Wilding, John P. H., et al. ‘Once-Weekly Semaglutide in Adults with Overweight or Obesity’. New England Journal of Medicine, vol. 384, no. 11, Mar. 2021, pp. 989–1002. DOI.org (Crossref), https://doi.org/10.1056/NEJMoa2032183.
- Frías, Juan P., et al. ‘Efficacy and Safety of Once-Weekly Semaglutide 2·0 Mg versus 1·0 Mg in Patients with Type 2 Diabetes (SUSTAIN FORTE): A Double-Blind, Randomised, Phase 3B Trial’. The Lancet Diabetes & Endocrinology, vol. 9, no. 9, Sept. 2021, pp. 563–74. DOI.org (Crossref), https://doi.org/10.1016/S2213-8587(21)00174-1.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025.
- PMDA: Mounjaro subcutaneous injection Ateos, prescription drug information
- PMDA: Wegovy subcutaneous injection, prescription drug information
Using Mounjaro for purposes other than type 2 diabetes is off-label use, and use for weight loss is self-pay treatment. Effects and side effects vary from person to person.
Medically reviewed by: Dr. Hiroko Oka (Chair, Medical Corporation Fukubikai; Certified Member, Japanese Society of Internal Medicine)



